HIGH PROTEIN
Adequate protein intake is essential to help minimise declines in strength and function5
THE POWER OF HMB IN SUPPORTING PATIENTS’ MUSCLE MAINTENANCE AND RECOVERY
Muscle is a dynamic tissue. It is continually in a cycle of synthesis and breakdown (or degradation), building new tissue and breaking down old.1-2 To maintain muscle mass, the goal is to ensure that muscle breakdown is not happening faster than muscle synthesis.2
But as we age, this can become more difficult, as muscle loss naturally accelerates due to muscle breakdown increasing and muscle synthesis reducing. This problem is compounded by hospitalisation, mobility limitations or catabolic illness. For example, in patients who are frail, have cancer or COPD.3
We know that protein plays a significant role in muscle health. But where breakdown is happening faster than synthesis, consuming dietary protein may not be enough to restore the balance.3
This is where HMB comes in. It has three mechanisms of action. It supports muscle synthesis, whilst uniquely protecting muscle from breakdown. It also helps to stabilise muscle cell membranes, thereby improving the repair of damaged muscle cells.***,°,>,|,4-7
FIND OUT MORE ABOUT THE IMPORTANT ROLE HMB PLAYS IN MUSCLE MAINTENANCE.
Specialised ONS containing HMB have been proven to have a positive effect on patients with long-term health conditions.
.png){kind=icon}
CANCER
ONS containing HMB is proven to preserve muscle mass and function in cancer patients and can also positively impact hospitalisation outcomes, cancer-related toxicity and survival rates.9♢♢
COPD
ONS containing HMB has been shown to benefit muscle mass and strength in COPD patients and has been proven to reduce the risk of death by 71% in malnourished COPD patients**10
FRAILTY
ONS containing HMB has been shown to benefit mobility, accelerate wound healing and increase muscle strength in patients undergoing surgery for hip fracture§§,\,◆,♢,11
THE POWER OF ABBOTT’S ONS WITH A UNIQUE BLEND CONTAINING HMBAbbott’s unique blend of high protein, HMB and vitamin D is clinically proven to help reduce muscle loss and support strength and recovery
from illness, injury and surgery.12-14
Adequate protein intake is essential to help minimise declines in strength and function5
HMB is a metabolite of leucine, a branched-chain essential amino acid exclusively obtained from dietary sources15
Acts directly on muscle to promote its function through specific vitamin D receptors found on muscle cells16
More than 18 clinical studies have shown that Abbott’s ONS with a unique blend, including HMB, can improve patient outcomes
in more ways than one:
In this 25-minute podcast episode, Dr Suzette Pereira discusses how muscle mass can impact the health status and outcomes of severely ill patients, and how ingredients like HMB can support recovery.
This infographic highlights the role of leucine and its metabolite HMB in supporting muscle health in aging and illness.
Footnotes:
COPD - Chronic obstructive pulmonary disease.
***HMB (Beta-hydroxy-beta-methylbutyrate) is an active metabolite of leucine, among the constituent elements of proteins, naturally found in some foods, but in small quantities.
°Studied in healthy young males, over a period of 2.5 hours after receiving HMB supplementation.
>Compared to baseline at post-absorptive state.
|In a RCT including 19 healthy adults aged ≥60 years confined to bed rest for 10 days. CaHMB (3 g daily) prevented the decline in total LBM over bed rest (-0.17 ± 0.19 kg; p =0.23) in treated group versus control group (-2.05±0.66 kg; p =0.02). \Postoperative nutrition provided 1900 kcal and 76 g protein a day.
♢Study design: A randomised control trial to investigating the effects of a specialised ONS on 75 older malnourished women (≥65 years) who underwent surgery for hip fracture vs standard post operative nutrition. Patients were mobile and ambulatory before the fracture.
◆Patients in the intervention group (n=32) + specialised ONS§. Patients in the control group (n=30) received standard post-operative nutrition (1900 kcal, 76 g protein per day) alone.
*In older community living adults (>60 years) receiving outpatient care with or at risk of malnutrition.
†In 283 adult patients with or at risk of malnutrition under standard of care, 63% being cancer patients.
‡In 62 community-dwelling pre-frail older people taking a specialised ONS vs nutritional counselling over 12 weeks.
§In 61 patients undergoing radical cystectomy receiving either a specialised ONS or vitamin/mineral supplement twice daily for 8 weeks.
||In 92 patients aged 65 and over with hip fractures admitted to a rehabilitation facility, either receiving a standard diet plus 2 bottles of the study product or a standard diet only. Standard diet provided 1500 kcal, 87.4 g protein a day.
¶An open-label study of elderly (n=35) patients with recent weight loss (>5% during previous 3 months) showed that 12 weeks supplementation of experimental product twice daily increased dietery intake, biochemical variables, and quality of life compared to baseline.
~As shown in a randomised controlled trial in which normally nourished patients with non-cystic fibrosis bronchectasis received pulmonary rehabilitation plus a specialised ONS or pulmonary rehabilitation only for 12 weeks. In the intervention group, mean and maximum handgrip dynamometry, physical functioning domain of QOL-B-V3.0 and other outcomes were significantly increased from baseline at 12 weeks and 24 weeks and fat free mass at 12 weeks.
**As shown in a randomised control trial to investigate the effects of the intervention ONS on malnourished, cardiopulmonary patients (≥65 years) vs placebo. The intervention ONS decreased mortality at 90 days post-discharge, however the study did not observe a significant effect for the primary composite endpoint of non-elective readmission or death. This post-hoc, sub-group analysis from the NOURISH study cohort comprised 214 COPD patients.
††Strength was measured by handgrip strength in a post hoc analysis of over 600 malnourished people with heart or lung diseases, age 65 or older. Study product was consumed twice a day for 30 days, as compared to standard of care.
‡‡In 330 older adults with malnutrition and sarcopenia. Muscle quality was calculated as leg strength expressed relative to the muscle mass.
§§As shown in a randomised control trial to investigate the effects of a specialised ONS on older women (≥65 years) who underwent surgery for hip fracture vs. standard post-operative nutrition. Post-operative nutrition provided 1900 kcal and 76 g protein a day. Muscle function was measured by handgrip strength. Mobilisation status was assessed on post-operative days 15 and 30.
¶¶In 65 healthy older female patients who regularly attended a fitness programme.
#In a single arm open-label study of 148 patients aged 80±8.3 years with or at risk of malnutrition who consumed experimental product twice daily for 12 weeks as compared to baseline.
##As shown in a randomised control trial to investigate the effects of the intervention ONS on malnourished, cardiopulmonary patients (≥65 years) vs placebo. The intervention ONS decreased mortality at 90 days post-discharge, however the study did not observe a significant effect for the primary composite endpoint of non-elective readmission or death.
~~In 102 nursing home residents ≥75 years old randomised into an intervention group (the intervention consisted of a combinationof sit-to-stand test 4 times/day and 2 bottles of a high protein low volume ONS) or a control group for 12 weeks.
♢♢A systematic review of 15 studies (n=943) published up to December 2021 including adults patients with various cancer types and treatments consuming HMB-ONS for 10 days-6 months
References:
1.Carbone JW &Pasiakos SM. Nutrients 2019;11(5):1136.
2. Tipton KD et al. Sports Med 2018;48(1):53-64.
3. Argilés JM et al. J Am Med Dir Assoc 2016;17(9):789-96.
4. Wilkinson DJ et al. J Physiol 2013;591:2911-23.
5. Deutz NE et al. Clin Nutr 2014;33(6):929-936.
6. Nissen SL & Abumrad NN. J Nutr Biochem 1997;8:300-311.
7. Deutz NEP et al. Clin Nutr 2013;32:704-712.
8. Engelen MPKJ & Deutz NEP. Curr Opin Clin Nutr Metab Care 2018;21(3):207-213.
9. Prado CM et al. J Cachexia, Sarcopenia Muscle 2022;13:1623–1641.
10. Deutz NE et al. Clin Nutr 2020: doi: 10.1016/j.clnu.2020.08.031.
11. Ekinci O et al. Nutr Clin Pract 2016;31(6):829-835.
12. Wolfe RR Am J Clin Nutr 2006;84:475-482.
13. Ceglia L Curr Opin Clin Nutr Metab Care 2009;12(6):628-633.
14. Bear DE et al. Am J Clin Nutr 2019;109(4):1119-1132.
15. Wilson GJ et al. Nutr Metab 2008;5:1.
16. Wagatsuma A and Sakuma K. Biomed Res Int 2014;2014:121254.
17. Ritch CR et al. J Urol 2019;201(3):470 477.
18. Chavarro Carvajal DA et al. Clin Nutr ESPEN 2022;48:291-297.
19. Cornejo Pareja I et al. Nutrients 2021;13(12):4355.
20. Peng LN et al. J Nutr Health Aging 2021;25(6):767-773.
21. Malafarina V et al. Maturitas 2017;101:42-50.
22. De Luis DA et al. Nutr Hosp 2015;32(1):202 207.
23. Olveira G et al. Clin Nutr 2016;35(5):1015-1022.
24. Matheson EM et al. Clin Nutr 2021;40(3):844-849.
25. Deutz NE et al. Clin Nutr 2021;40(3):1388-1395.
26. Cramer JT et al. JAMDA 2016;17(11):1044-1055.
27. Berton L et al. PLoS One 2015;10(11):e0141757.
28. De Luis DA et al. Eur Geriatr Med 2018;9(6):809-817.
29. Deutz NE et al. Clin Nutr 2016;35(1):18-26.
SESSION TIMEOUT
You have now gained access to ProConnect for a limited time. We will now verify your details before your account becomes fully active.
You are now able to freely access all resources and education during this visit to the ProConnect website. An email will be sent to you within 2 working days to activate your account which will complete your registration process.
Added to Bag
ENSURE PLUS
1 x 220 ml
Flavor: Apple
1,5 kcal / ml
Nutrition Information
| Unit | Per {ml-col-1} ml | Per {ml-col-2} ml |
| Unit | Per {ml-col-1} ml | Per {ml-col-2} ml |
| Unit | Per {ml-col-1} ml | Per {ml-col-2} ml |
footnotes
Product details not available.
You are about to exit for another Abbott country or region specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimised for your specific screen size.
Do you wish to continue and exit this website?
UK-N/A-2200465 | July 2022
This website is for UK HCPs and UK Patients only. If you are outside of the UK please visit our global website Abbott.com
If you choose "I am a patient/carer”, you will be entering a website intended for patients and carers which has information on Abbott products. Products on this website are to be used under medical supervision. If you have questions about the product information discussed on this website, you should consult with your healthcare professional.
Stay Connected